Anglo-Norwegian pharmaceutical company Nycomed Amersham of Buckinghamshire, U.K., has tapped John Padfield as CEO of its Nycomed Amersham Imaging contrast division. Padfield joins the company from U.K. pharmaceutical firm Chiroscience Group and
Anglo-Norwegian pharmaceutical company Nycomed Amersham of Buckinghamshire, U.K., has tapped John Padfield as CEO of its Nycomed Amersham Imaging contrast division. Padfield joins the company from U.K. pharmaceutical firm Chiroscience Group and will succeed Guy Marlow as chief of Nycomed Amershams global contrast business. Marlow is retiring later this year.
FDA Clears CT-Based AI Tools for PE Detection and Stroke Severity Assessment
March 26th 2024The artificial intelligence (AI) modalities CINA-iPE and CINA-ASPECTS may facilitate improved detection of incidental pulmonary embolism and stroke evaluation, respectively, based on computed tomography (CT) scans.